VERX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vertex Inc (VERX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there is potential upside based on analyst price targets, the company's financial performance, technical indicators, and mixed analyst sentiment suggest caution. The stock may be worth monitoring for future opportunities, but it does not present a compelling entry point right now.
The technical indicators for VERX are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 32.687, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 13.91, with key support at 12.302 and resistance at 15.519.
Goldman Sachs recently upgraded the stock with a buy rating and increased the price target to $23, reflecting optimism. The stock has a potential upside of 122.89% based on analyst projections. Additionally, the new CEO's focus on innovation and AI integration could drive long-term growth.
The company's Q4 financials showed significant declines in net income (-89.67% YoY) and EPS (-90.70% YoY). Gross margin also dropped slightly. Analysts have broadly lowered price targets, citing slowing subscription growth, elevated churn, and elongated sales cycles. Near-term headwinds and volatility are expected. Technical indicators are bearish, and there are no significant insider or hedge fund trading trends.
In Q4 2025, revenue increased by 9.11% YoY to $194.71 million, but net income dropped significantly to -$7.003 million (-89.67% YoY), and EPS fell to -0.04 (-90.70% YoY). Gross margin also declined slightly to 61.48%. These results indicate challenges in profitability and operational efficiency.
Analyst sentiment is mixed. While Goldman Sachs and Citizens maintain optimistic outlooks with buy/outperform ratings, most analysts have lowered price targets significantly, citing disappointing Q4 results, slowing growth, and near-term challenges. Ratings range from Neutral to Outperform, with price targets between $13 and $25.
